Sapanisertib

Drug Profile

Sapanisertib

Alternative Names: Dual TORC1/2 inhibitor - Millennium Pharmaceuticals; HY 13328; INK 128; MLN-0128; Oral mTORC1/2 inhibitor MLN0128 - Millennium Pharmaceuticals; TAK 228

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Intellikine
  • Developer Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); National Cancer Institute (USA); Takeda; Takeda Oncology
  • Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours; Renal cell carcinoma; Soft tissue sarcoma; Thyroid cancer
  • Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
  • No development reported Solid tumours
  • Discontinued Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 18 May 2017 Avera McKennan Hospital & University Health Center plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in USA (NCT03154294)
  • 24 Apr 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Newly diagnosed, Neoadjuvant therapy) in USA (PO) (NCT02988986)
  • 17 Apr 2017 Yale University and National Cancer Institute initiate enrolment in a phase II trial for Bladder Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (NCT03108261)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top